Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma

Abstract 6: Expression profiling of laser micro dissected prostate cancer cells delineates genes associated with biochemical recurrence after radical prostatectomy.

(2014) Martin M. Mortensen et al.   CANCER RESEARCH

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation

(2014) N. Rodi  et al.   Cancer Immunology Research

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD